You just read:

Xynomic Pharma and UCSF Entered Strategic Partnership in Conducting a Phase 2/3 Trial of Abexinostat against Renal Cell Carcinoma

News provided by

Xynomic Pharmaceuticals, Inc.

May 22, 2017, 08:16 ET